Top

Published in:

01-03-2001

Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches

Authors: Robert S. Kerbel, Joanne Yu, Jennifer Tran, Shan Man, Alicia Viloria-Petit, Giannoula Klement, Brenda L. Coomber, Janusz Rak

Published in: Cancer and Metastasis Reviews | Issue 1-2/2001

Title: Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
Authors: Robert S. Kerbel
Joanne Yu
Jennifer Tran
Shan Man
Alicia Viloria-Petit
Giannoula Klement
Brenda L. Coomber
Janusz Rak
Publication date: 01-03-2001
Publisher: Kluwer Academic Publishers
Published in: Cancer and Metastasis Reviews / Issue 1-2/2001
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1023/A:1013172910858

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1-2/2001

Translational Regulation as a Novel Mechanism for the Development of Cellular Drug Resistance

Tumor Physiology and Drug Resistance

Adjuvant Treatment of Colorectal Cancer: Towards Tumor-specific Immunotherapies

The Challenge of Pathway and Environment-mediated Drug Resistance

Resistance to Rapamycin: A Novel Anticancer Drug

Malignant Cells, Directors of the Malignant Process: Role of Transforming Growth Factor-beta

Keynote webinar | Spotlight on antibody–drug conjugates in cancer